20212020201920182017201620152014 July 02, 2021 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 30, 2021 Summary ToggleSpero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206 June 15, 2021 Summary ToggleSpero Therapeutics Announces the Initiation of Bronchoalveolar Lavage and Renal Impairment Clinical Trials of SPR206 May 28, 2021 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 17, 2021 Summary ToggleSpero Therapeutics Awarded up to $23 Million by the National Institute of Allergy and Infectious Diseases to Support the Development of SPR206 May 13, 2021 Summary ToggleSpero Therapeutics to Participate at the Berenberg Conference USA May 06, 2021 Summary ToggleSpero Therapeutics Announces First Quarter 2021 Operating Results and Provides Business Update April 30, 2021 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 29, 2021 Summary ToggleSpero Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 March 31, 2021 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Pagination First page First Previous page Previous Page 1 Current page 2 Page 3 Page 4 … Next page Next Last page Last
